---
title: "Medpace FY26 Q2 net income rises to $121.36 million; revenue climbs 17.2% to $707.33 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293661248.md"
description: "Medpace reported Q2 FY26 net income of $121.36 million, up $31.1 million year-over-year, with revenue climbing 17.2% to $707.33 million driven by growth in Metabolic, Oncology, CNS, and AVAI programs. Operating income rose to $146.82 million, while the backlog increased 4.9% to $3.01 billion. The company also recorded $795.7 million in new business awards and repurchased shares worth $294.7 million."
datetime: "2026-07-23T20:11:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293661248.md)
  - [en](https://longbridge.com/en/news/293661248.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293661248.md)
generator: "portal-rs"
---

# Medpace FY26 Q2 net income rises to $121.36 million; revenue climbs 17.2% to $707.33 million

-   Medpace posted Q2 net income of USD 121.36 million, up USD 31.1 million from a year earlier. \* Revenue climbed 17.2% to USD 707.33 million, driven by growth in Metabolic, Oncology, CNS and AVAI programs. \* Operating income rose to USD 146.82 million; interest income, net more than doubled to USD 4.99 million. \* Backlog increased 4.9% to USD 3.01 billion, with about USD 1.95 billion to USD 1.97 billion expected to convert within 12 months. \* Net new business awards reached USD 795.7 million; share repurchases totaled USD 294.7 million, leaving USD 527 million authorized. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001668397-26-000025), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MEDP.US](https://longbridge.com/en/quote/MEDP.US.md)

## Related News & Research

- [Medpace CEO August Troendle sells 15,978 shares for $9.98 million](https://longbridge.com/en/news/297034410.md)
- [Medpace director Fred B. Davenport Jr disposes of 7,283 common shares for $4.41 million](https://longbridge.com/en/news/296649041.md)
- [Top Medpace Executive Makes Bold Insider Move in High-Value Stock Sale](https://longbridge.com/en/news/296848598.md)
- [Major Insider Shake-Up at Medpace Sends Investors Scrambling](https://longbridge.com/en/news/296983204.md)
- [Medpace Holdings (MEDP) Rallies As Valuation Questions Grow](https://longbridge.com/en/news/296681298.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**